Here are the 10-K annual reports from Greater Cannabis Co (GCAN) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow GCAN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full GCAN filings page.
The Greater Cannabis Company, Inc. reported a full-year 2025 net loss of $331,612 on $0 in revenue, similar to 2024. Operating expenses rose to $183,005 from $156,276, reflecting ongoing development activity without commercial sales.
Cash declined to $815 at December 31, 2025, against current liabilities of $742,464, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management is focused on a licensed cannabinoid therapy from Shaare Zedek Scientific and plans a Phase II clinical trial once specialized API is sourced and additional funding is raised. During 2025 the company completed a 1-for-1,500 reverse stock split and created Series B Preferred Shares, giving its CEO majority voting control while common shares outstanding reached 944,935 as of March 16, 2026.